BMS builds on Eliquis and Sotyktu direct-to-patient program

US pharma major Bristol Myers Squibb (NYSE: BMY) has announced an expansion of its direct-to-patient offerings, providing eligible US patients with steeply discounted prices for Eliquis (apixaban) and Sotyktu (deucravacitinib).

Eligible cash-pay patients can now purchase these medicines directly from BMS and significantly lower their out-of-pocket costs.

Beginning January 2026, Sotyktu, BMS’ medicine for moderate-to-severe plaque psoriasis, will be offered through the new BMS Patient Connect platform, which follows the launch of the firm’s Bristol Myers Squibb-Pfizer Alliance program for Eliquis earlier this month. The platform will offer Sotyktu at more than 80% less than the current list price.